FDA Starts Process For Regulating Next-generation Vaccine Adjuvants
This article was originally published in The Pink Sheet Daily
Executive Summary
Scientific meeting planned for late fall or early spring.
You may also be interested in...
Sticking Point: Cervarix Outshines Gardasil, But Practical Value Is Unclear
Merck says immune response trial provides "no clinically relevant information."
Sticking Point: Cervarix Outshines Gardasil, But Practical Value Is Unclear
Merck says immune response trial provides "no clinically relevant information."
GlaxoSmithKline Looks To Revamp U.S. Operations In Tough Environment
U.S. sales fell 13 percent in the third quarter due to generic competition and Avandia.